Sucunamostat is under clinical development by Scohia Pharma and currently in Phase II for Diabetic Nephropathy. According to GlobalData, Phase II drugs for Diabetic Nephropathy have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sucunamostat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sucunamostat overview

Sucunamostat (SCO-792) is under development for the treatment of obesity subjects with type 2 diabetes, albuminuria, diabetic nephropathy, non-alcoholic steatohepatitis (NASH), chronic kidney disease and obesity. It is administered orally. The drug candidate targets enteropeptidase enzyme.

Scohia Pharma overview

Scohia Pharma is a bio-pharmaceutical company which develops and commercializes novel therapeutics for metabolic, cardiovascular and renal diseases. The company product pipeline includes SCO-272, SCO-792, SCO-094, SCO-267, SCO 240, SCO 006 and SCO 116. Its SCO-272 candidates acts as an an inhibitor for the treatment of hypertension, SCO-792 is an oral drug for the treatment of obesity, SCO-094 is an injectable peptide for the treatment of diabetes and SCO-267 is an oral agonist. Scohia Pharma services comprises pharmacological research, synthetic research and clinical development, among others. It serves in the therapeutic areas of blood glucose, blood pressure and lipids. Scohia Pharma is headquartered in Fujisawa, Kanagawa, Japan.

For a complete picture of Sucunamostat’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.